The 13 drugs most likely to be chosen for CMS negotiations, according to the study: Ozempic, Rybelsus and Wegovy (semaglutide): Novo Nordisk's treatment for Type 2 diabetes and weight management.
cSchool of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China dDepartment of Biomedical Informatics, School of Basic Medical Sciences ...